management needs to get their product out like never before and into the hands of every school in the country and even get them into the hands of every major factory nurse in the world.
i'm saying most consumers can self-diagnose their own flu symptoms and doctors generally do it without any test, so having a quick flu test will be a money-loser product for orasure.
on the separate subject of HIV and HCV tests, the money is NOT in testing.... the money is being made by the big pharma supplying the treatment drugs. abbott said as much when they abandoned orasure a few years ago and nothing has changed. i can get a free HIV in numerous places and orasure hasn't been able to successfully demonstrate that avg consumers (i.e. outside the higher risk gay & multi-partner active communities) must be tested at-home (for privacy) or at the doctor's office with regularity as CDC had wanted. the facts are overwhelming... OTC/HIV sales are unimpressive and as a former OSUR investor who had been led to believe the OTC/HIV sales would be big... it hasn't. HCV testng is the same. orasure doesn't own the market for tests in either HIV or HCV... there are numerous test manufacturers that supply the medical community here in USA and internationally.
ebola test will also be a money-loser... cost too much and sell be sold with little margin. pre-emptive vaccinations appear to be the better way to go here and mitigate the need for a field-level quick test.
my goal is to invest and make money, not be an advocate for a product/company. in fact, i like the orasure product line, but dislike the mgmt and how it's behaved. if they didn't buyout DNA Genotek this company would have a $2 stock as the orasure side of business is and has been underperforming for quite some time. i regret not being able to own stock in DNA Genotek by itself.
nevertheless, OSUR can still be a fun stock to swing trade from time to time but no way would i ever again put serious capital in this stock as a long-term investment. if i want risk, i'd play biotech for better rewards. OSUR is a different animal completely, neither biotech, growth, or value investment. it's a "story" stock.
Medicare will cover if baby boomer or prior IV drug use. Medicare does NOT say what test they accept only their criteria. link:
assuming OSUR test is FDA approved, then it should be covered under conditions and age and such above. Now that we have an actual treatment and usual CURE for HCV , I think bodes well for OSUR...
The "treatment" side of HCV is another discussion. Drugs for roughly 70% cure rate are very expensive. Am sure that discussion will come up in future. (On medicare coverage or not). Given that HCV is known to lead to liver cancer...going to hard for CMS to deny treatment for cure.
Great question ; dont know the answer , but it would likely fall under the 30 pages of an insurance policy which wants physicians to limit tests and imaging studies ...unless "medically justified"...
My guess is (commercial insurance generally follows what Medicare allows as valid testing) is if the patient has risk factors, voices concerns, and since there are now treatments for first time for HCV , that they could not deny payment for rapid HCV . It is a silent killer and leads to liver cancer. Prudent physicians should inquire about risk factors for HCV and if documented in medical record, cant see insurance companies being able to deny test as medically "unnecessary". Esp. now there are a couple drugs on market that have reasonable "cure " rates. HCV is highly associated with liver cancer.
Great question though, makes a big difference in how this company does in future.
are you saying physicians can "diagnose" HIV and HCV based on symptom and physical examination? If so, you are wrong. both HIV and HCV often have no symptoms. Unless one suspects HIV in the acute phase, a viral illness, your assumptions are wrong. Vast Majority of HCV infected patients have NO symptoms. but puts them at much higher risk for Liver Cancer.
Please clarify what you posted
IOC, Orasure execs may well be overpaid and mediocre, but you say they have bonuses tied directly to whether or not they beat earnings estimates made by analysts? That would be extraordinarily unusual.
Guiding low is, I am sure you know, a pretty standard operating procedure for a slew of companies. Me I muchprefer it to consistently guiding too high, but to each their own.....
. But whatever the guidance, analysts finally make their own projections.
Stating it as a hidden undervalued stock Gem with great upside potential and Products sale increasing by 100% this years. It Also mentions Zacks stock recommendation as a "STRONG BUY" at these levels. Good to see it is being written about on Yahoo in such a positive way. Need more Public awareness of this Stocks potential.
@teamecss, if you had bothered to do DD, you would see that the management has ALWAYS estimated low for next quarter earnings and then always beat them in order to collect large bonuses. Go back and review the earnings for the last ten plus years and then tell me I'm wrong. Ask Pesotrader or Gben1938, they are both long term followers of this stock and will corroborate my statement.
Chart shows clear bottom on very large volume.
Millennium Healthcare (MHCC) reported revenues increased over 400% in 2014 to over $8 million
Total market cap today at $0.01 per share equals less than $2 million.
At only 10X revenues shares should be selling at $.45 today.
Aggressive growth - Recently acquired HealthPath and MedX with more to be announced
New management is very strong, capable and with strong healthcare relationships. New CEO and President already grew $1.3 Billion sales in previous company.
Revenues set to explode again in 2015.
Expect big runway of new FDA approved early detection diagnostics for heart and cancer.
Small investment has potential for huge gains this year.
Keep MHCC in your portfolio and watch closely for frequent news of big changes
MHCC 12 month price target - $1.25
Sentiment: Strong Buy
to ask if its not past time to sell the company off. The only beneficiaries of this POS are the upper mgmt. Michels had compensation of $2.5 MILLION in 2014. Totally ridiculous.
sell on the news. these sales (way in the future) generate no profits.
also, the new strategy is to vaccinate everyone in contact group before
they can get ebola, so lower need for emergency test.
Pre-market has shown signs of life after the news about the Ebola testing authorisation. Fingers crossed this is an upward trend which will hold strong and continue to finally put money back into our funds.